# US 2019/0315725 A1 · Combination therapy for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315725 A1
- Document ID: US20190315725A1
- Status: Published application
- Kind: A1
- Application number: 16/372,657
- Filed: 2019-04-02
- Published: 2019-10-17
- Earliest claimed: 2012-04-13
- Assignees: Epizyme, Inc.
- Applicants: Epizyme, Inc.
- Inventors: Heike KEILHACK; Sarah Kathleen KNUTSON; Kevin Wayne KUNTZ
- Web page: https://patentgrep.com/patent/US20190315725A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/64: attached in position 2 or 6
- C07D 413/14: containing three or more hetero rings
- A61K 33/24: Heavy metals; Compounds thereof
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

## Claims

### Claim at position 1

-11. (canceled)

### Claim 12

A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective dose of a compound of Formula (IIa):
or a pharmaceutically acceptable salt thereof and a therapeutically effective dose of rituximab, wherein
each of Ra and Rb, independently, is H or C1-C6 alkyl; or Ra and Rb, together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatoms; wherein the C1-C6 alkyl or the 4 to 7-membered heterocycloalkyl ring are optionally substituted with one or more -Q3-T3, in which Q3 is a bond or unsubstituted or substituted C1-C3 alkyl linker, and T3 is H, halo, 4 to 7-membered heterocycloalkyl, C1-C3 alkyl, ORd, COORd, —S(O)2Rd, or —NRdRe, in which each of Rd and Re is independently H or C1-C6 alkyl, or -Q3T3 is oxo;
R7 is isopropyl or C1-C6 alkyl, C3-C8 cycloalkyl, piperidinyl, tetrahydropyran, tetrahydro-2H-thiopyranyl,cyclopentyl, or cyclohexyl, or 4 to 12-membered heterocycloalkyl, each optionally substituted with one or more -Q5-T5, in which Q5 is a bond, C(O), C(O)NRk, NRkC(O), S(O)2, or C1-C3 alkyl linker, Rk being H or C1-C6 alkyl, and T5 is H, halo, C1-C6 alkyl, hydroxyl, cyano, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or S(O)qRq in which q is 0, 1, or 2 and Rq is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and T5 is optionally substituted with one or more substituents selected from the group consisting of halo, C1-C6 alkyl, hydroxyl, cyano, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl except when T5 is H, halo, hydroxyl, or cyano; or -Q5-T5 is oxo; and
R8 is H, methyl, or ethyl;
wherein the cancer is resistant or refractory to at least one prior therapy; and
wherein the compound of Formula (IIa) and said rituximab are administered simultaneously or sequentially.

### Claim 13 (depends on 12)

The method of claim 12, wherein the compound of Formula (IIa) or a pharmaceutically acceptable salt thereof, is administered prior to administration of said rituximab.

### Claim at position 4

-27. (canceled)

### Claim 28 (depends on 12)

The method of claim 12, wherein said subject has demonstrated resistance to the compound of Formula (IIa) or a pharmaceutically acceptable salt thereof when administered as a single agent.

### Claim at position 6

-33. (canceled)

### Claim 34 (depends on 12)

The method of claim 12, wherein the cancer is lymphoma, leukemia, or melanoma.

### Claim at position 8

-37. (canceled)

### Claim 38 (depends on 34)

The method of claim 34, wherein the cancer is follicular lymphoma.

### Claim 39 (depends on 12)

The method of claim 12, wherein the cancer is resistant to at least one prior monotherapy.

### Claim 40 (depends on 12)

The method of claim 12, wherein the cancer is resistant to at least one prior combination therapy.

### Claim 41 (depends on 12)

The method of claim 12, wherein said subject has demonstrated resistance to rituximab when administered as a single agent.

### Claim 42 (depends on 12)

The method of claim 12, wherein the compound of Formula (IIa) is Compound 44:
or a pharmaceutically acceptable salt thereof.

### Claim 43

A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective dose of a compound of Formula (IIa):
or a pharmaceutically acceptable salt thereof, a therapeutically effective dose of rituximab, and a therapeutically effective dose of lenalidomide, wherein
each of Ra and Rb, independently, is H or C1-C6 alkyl; or Ra and Rb, together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatoms; wherein the C1-C6 alkyl or the 4 to 7-membered heterocycloalkyl ring are optionally substituted with one or more -Q3-T3, in which Q3 is a bond or unsubstituted or substituted C1-C3 alkyl linker, and T3 is H, halo, 4 to 7-membered heterocycloalkyl, C1-C3 alkyl, ORd, COORd, —S(O)2Rd, or —NRdRe, in which each of Rd and Re is independently H or C1-C6 alkyl, or -Q3T3 is oxo;
R7 is isopropyl or C1-C6 alkyl, C3-C8 cycloalkyl, piperidinyl, tetrahydropyran, tetrahydro-2H-thiopyranyl,cyclopentyl, or cyclohexyl, or 4 to 12-membered heterocycloalkyl, each optionally substituted with one or more -Q5-T5, in which Q5 is a bond, C(O), C(O)NRk, NRkC(O), S(O)2, or C1-C3 alkyl linker, Rk being H or C1-C6 alkyl, and T5 is H, halo, C1-C6 alkyl, hydroxyl, cyano, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or S(O)qRq in which q is 0, 1, or 2 and Rq is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and T5 is optionally substituted with one or more substituents selected from the group consisting of halo, C1-C6 alkyl, hydroxyl, cyano, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl except when T5 is H, halo, hydroxyl, or cyano; or -Q5-T5 is oxo; and
R8 is H, methyl, or ethyl;
wherein the cancer is resistant or refractory to at least one prior therapy; and
wherein the compound of Formula (IIa) and said rituximab and said lenalidomide are administered simultaneously or sequentially.

### Claim 44 (depends on 43)

The method of claim 43, wherein the compound of Formula (IIa) or a pharmaceutically acceptable salt thereof, is administered prior to administration of said rituximab, said lenalidomide, or a combination of said rituximab and said lenalidomide.

### Claim 45 (depends on 43)

The method of claim 43, wherein the cancer is resistant to at least one prior monotherapy.

### Claim 46 (depends on 43)

The method of claim 43, wherein said subject has demonstrated resistance to the compound of Formula (IIa) or a pharmaceutically acceptable salt thereof when administered as a single agent.

### Claim 47 (depends on 43)

The method of claim 43, wherein the cancer is resistant to at least one prior combination therapy.

### Claim 48 (depends on 43)

The method of claim 43, wherein said subject has demonstrated resistance to lenalidomide when administered as a single agent.

### Claim 49 (depends on 43)

The method of claim 43, wherein said subject has demonstrated resistance to rituximab when administered as a single agent.

### Claim 50 (depends on 43)

The method of claim 43, wherein said subject has demonstrated resistance to rituximab and to lenalidomide when administered as single agents or in combination.

### Claim 51 (depends on 43)

The method of claim 43, wherein the cancer is lymphoma, leukemia, or melanoma.

### Claim 52 (depends on 51)

The method of claim 51, wherein the cancer is follicular lymphoma.

### Claim 53 (depends on 43)

The method of claim 43, wherein the compound of Formula (IIa) is Compound 44:
or a pharmaceutically acceptable salt thereof.
